Last updated on September 2018

Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor

Brief description of study

The aim of this study is to determine if the Investigational Medicinal Product Tedopi (OSE2101) is more effective than standard treatment in treating patients with stage IIIB NSCLC unsuitable for radiotherapy or metastatic NSCLC in second- or third-line treatment after failure of immune checkpoint-inhibitor regimens.

Clinical Study Identifier: NCT02654587

Find a site near you

Start Over

Gesinger Medical Center

Danville, PA United States
  Connect »

CHU Montpellier

Montpellier, France
  Connect »

Krajsk nemocnice Liberec

Liberec, Czech Republic
  Connect »

Cancer Center at West Jefferson

New Orleans, LA United States
  Connect »

Meridian Health

Neptune, NJ United States
  Connect »

Gettysburg Cancer Center

Gettysburg, PA United States
  Connect »

Millenium Oncology

Houston, TX United States
  Connect »

Stephenson Cancer Center

Oklahoma City, OK United States
  Connect »

Pontchartrain Cancer Center

Covington, LA United States
  Connect »

Georgetown University Hospital

Washington, WA United States
  Connect »

Pardubick krajsk nemocnice

Pardubice, Czech Republic
  Connect »

CHU Grenoble

Grenoble, France
  Connect »

Genesis Cancer Center

Hot Springs, AR United States
  Connect »

Pennington Cancer Center

Baton Rouge, LA United States
  Connect »

Matrai Gyogyint zet

Mátraháza, Hungary
  Connect »